Among diabetic patients, diabetic retinopathy is an eye disease. It is of two types, non-proliferative diabetic retinopathy and proliferative advanced diabetic retinopathy. The early phase of the disease in which the blood vessels in the retina are weakened is non-proliferative diabetic retinopathy. The developed form of disease in which the retina is deprived of oxygen owing to circulation issues is proliferative diabetic retinopathy. Tests such as fluorescein angiography and optical coherence tomography can be used to diagnose diabetic retinopathy. The treatment includes injection of intraocular steroid, laser therapy, anti-VEGF therapy, vitrectomy, and others. The diabetic retinopathy market shows potential development with increased diabetes incidence and increased awareness of diabetes management.
Get Free Sample Report: https://www.wiseguyreports.com/sample-request/4532899-global-diabetic-retinopathy-market
Companies are taking strategic measures such as acquisitions, mergers, geographic expansion and product development to promote their companies and boost their business outreach. ThromboGenics, for example, launched a collaboration with Novartis (Alcon) to support JETREA outside the U.S. in comercialization and marketing. The key players operating in the market are BCN Peptides, Kowa Group, Ampio Pharmaceuticals, Glycadia Pharmaceuticals, Alimera Sciences, Genentech, Sirnaomics, Actavis Plc, ThromboGenics, Bayer Healthcare, and Novartis AG among others.
Market Dynamics: Drivers, Restraints, Opportunities Challenges
- High prevalence of disease and Favorable reimbursement policies available for ophthalmologic surgeries
Increasing diabetes prevalence along with increased incidence of diabetes-related blindness is expected to boost market growth over the forecast period. The number of individuals with diabetes has risen from 108 million adults in 1980 to around 422 million adults in 2014, according to World Health Organization estimates. Moreover, the worldwide incidence of diabetes also increased in 2014, at approximately 8.5% in the adult population, compared to 4.7% in 1980. Approximately 78.0 percent of diabetic retinopathy instances were recorded in 2013, according to statistics provided by the Department of Assistive and Rehabilitative Services (DARS), Texas, which could eventually lead to vision loss. Advantageous reimbursement policies for ophthalmologic surgery should have a positive impact on the development of the market for diabetic retinopathy. Diabetic retinopathy is a chronic condition in elderly individuals that affects the eyes and causes blindness. Laser treatment not just helps preserve eye sight, but also helps to prevent further damage caused by proliferative retinopathy with diabetes. Since technological interventions have occurred in these surgeries, elderly citizens in emerging economies are facing affordability problems owing to surgical cost hikes. Insurance suppliers such as Medicaid and Medicare are therefore implementing multiple policies to decrease the procedural expenses that are favorable to the growth of the industry.
- Technological Advancements and Multiple Treatment Options.
During the forecast years, technological advances in ophthalmic surgical and diagnostic tools will promote market growth in diabetic retinopathy. Tomography of optical coherence and other technologically upgraded devices used in diagnosis provide cross-sectional pictures of superior quality that enable doctor to make better choices. Furthermore, surgical instruments have increased precision to improve the success rates of surgery. The accessibility of such upgraded ophthalmic devices and tools has thus facilitated diagnostic and surgical procedures that have a positive impact on the development of the market during forecast period.
Diabetic retinopathy Market by Disease Type
Diabetic retinopathy Market by Management
- Anti VEGF
- Intraocular steroid injection
- Laser surgery
North America, Asia Pacific, Europe, Latin America, and Middle East & Africa can categorize the worldwide Diabetic retinopathy therapy market based on region. Due to the supporting reimbursement policies, North America accounted for the largest share and increased diabetes prevalence. One of the key factors contributing to the large regional share is the high market penetration of anti-VEGF medicines Avastin, Eylea and Lucentis. In addition, high healthcare spending, increasing patient awareness rates, and advanced healthcare infrastructure drive the market. Europe accounted for the second leading share in the market for diabetic retinopathy. The growing healthcare infrastructure in advanced European countries along with a favourable reimbursement structure is anticipated to boost market growth over the forecast period. Furthermore, growth is anticipated to fuel the existence of elevated unmet medical requirements in the developing Eastern European economies combined with quickly improving health infrastructure in the region. During the forecast period, developing economies such as China and India in Asia Pacific are expected to experience profitable development due to growing disposable income, increasing geriatric population, expanding diabetes research financing, diagnostic innovation, and huge target patient pool. Japan is the biggest market in the Asia Pacific area, largely due to heavy spending on healthcare and increasing disposable income. In addition, the increasing use of Lucentis is anticipated to drive this region’s market growth.
Diabetic retinopathy is considered a significant complication of long-term diabetes that threatens vision. Proliferative diabetic retinopathy was one of the leading causes of blindness in diabetic patients, accounting for a significant market share. The market growth is anticipated to be boosted by a rise in market vendors in emerging markets-Asia-Pacific and LAMEA regions. Several clinical trials have been conducted in recent years on the diabetic retinopathy market. The largest numbers of trials for diabetic retinopathy were reported in North America, followed by Europe. North America contributes for largest market share and anticipated to maintain its dominance throughout the forecast period.
Table of Contents
- Research Methodology
- Executive Summary
- Market Overview
- Industry Insights
- Diabetic retinopathy Market, by Disease Type
- Diabetic retinopathy Market, by Management
- Diabetic retinopathy Market, by Region
- Competitive Landscape
Read Other Reports from our Database :
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.
Ph: +162 825 80070 (US)
Ph: +44 203 500 2763 (UK)